PR Newswire·Aug 21, 2026, 8:00 AM ET

Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards

Azitra, Inc. (NYSE American: AZTR) received written notification on August 19, 2026, confirming it has regained compliance with all NYSE American continued listing standards.
The company resolved previously disclosed deficiencies under Sections 1003(a)(ii) & 1003(a)(iii) of the NYSE American Company Guide.
The "below compliance" (.BC) indicator will no longer be disseminated, & Azitra will be removed from the NYSE American noncompliant issuers list.
Azitra remains subject to continued listing monitoring procedures & faces potential delisting proceedings if noncompliance occurs again within 12 months.
CEO Francisco Salva stated the company is focused on advancing its ATR-COSF & ATR-04 programs to create shareholder value.
Azitra's portfolio includes ATR-COSF, a recombinant protein for cosmetic applications, & ATR-04, an investigational live biotherapeutic for EGFR inhibitor-associated rash with FDA Fast Track designation.
Forward-looking statements in the release outline expected timing for safety data & trial results for ATR-12, ATR-04, & ATR-COSF, subject to various risks including funding, regulatory approval, & clinical outcomes.